Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG56 in Grass Pollen Allergic Rhinitis and Rhinoconjunctivitis
NCT02654223Phase 2Completed
- Sponsor
- Inmunotek
- Start
- Dec 2015
- Primary completion
- Nov 2021
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of MG56 Mannosylated 5000 in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by Inmunotek. Started Dec 2015; status: completed.
02
Drugs
MG56 Mannosylated 5000
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02654223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654223.